Caliway Biopharmaceuticals
0
0
+$0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
11NovExpected
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.01
0.03
0.06
0.09
Expected EPS
-0.007783
Actual EPS
N/A
Financials
-916.62%Profit Margin
Unprofitable1.25MRevenue
-11.5MNet Income
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Taipei City, Taiwan.
Show more...
CEO
ISIN
TW0006919004
Listings
0 Comments
Share your thoughts
FAQ
What is Caliway Biopharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Caliway Biopharmaceuticals stocks are traded under the ticker CLBPF.
When is the next Caliway Biopharmaceuticals earnings date?▼
Caliway Biopharmaceuticals is going to release the next earnings report on November 11, 2026.
What is Caliway Biopharmaceuticals revenue for the last year?▼
Caliway Biopharmaceuticals revenue for the last year amounts to 1.25M USD.
What is Caliway Biopharmaceuticals net income for the last year?▼
CLBPF net income for the last year is -11.5M USD.
In which sector is Caliway Biopharmaceuticals located?▼
Caliway Biopharmaceuticals operates in the Other sector.
When did Caliway Biopharmaceuticals complete a stock split?▼
The last stock split for Caliway Biopharmaceuticals was on July 14, 2025 with a ratio of 10000:1000.